Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
Q1 2026 earnings • released • EPS beat +11,14% • Revenue beat +5,24%
See results
BMY:NYSE
Bristol-Myers Squibb Co
58,22 USD
-3,91%
(-2,37) 1D
58,50 USD
+0,48% (+0,28)
After hours
Closed: 1-май, 16:00:04 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BMY...
Open
60,02 USD
High
60,08 USD
Low
58,03 USD
Mkt. cap
118,87 млд
Volume
18,37 млн
Dividend
4,33%
Quarterly dividend
0,63 USD
Ex dividend date
2026-ж., 2-янв.
P/E ratio
16,34
52-wk high
62,89 USD
52-wk low
42,52 USD
EPS
3,56 USD
Beta
0,27
Shares outstanding
2,04 млд
No. of employees
32 миң
News stories
From sources across the web
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOChris Boerner
Employees32,5 миң
Founded1887
HeadquartersНью-Йорк, Нью Йорк, Америка Кошмо Штаттары
SectorPharmaceutical industry
Websitebms.com
Last report
2026-ж., 30-апр.
Fiscal Period
Q1 2026
Normalized EPS / Estimate
1,58/ (1,42 est.)USD
+11,14%beat
Revenue / Estimate
11,49 млд/ (10,92 млд est.)USD
+5,24%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
Revenue
12,27 млд
12,22 млд
12,50 млд
11,49 млд
Cost of goods sold
3,36 млд
3,31 млд
3,51 млд
3,42 млд
Cost of revenue
3,36 млд
3,31 млд
3,51 млд
3,42 млд
Research and development expenses
2,26 млд
2,43 млд
2,56 млд
2,65 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,69 млд
1,79 млд
2,09 млд
1,62 млд
Operating expense
4,78 млд
5,05 млд
5,47 млд
4,70 млд
Total operating expenses
8,14 млд
8,36 млд
8,98 млд
8,12 млд
Operating income
4,13 млд
3,86 млд
3,52 млд
3,36 млд
Other non operating income
399,00 млн
529,00 млн
544,00 млн
-32,00 млн
EBT including unusual items
1,77 млд
3,11 млд
1,47 млд
3,24 млд
EBT excluding unusual items
4,22 млд
4,07 млд
3,86 млд
3,33 млд
Income tax expense
460,00 млн
919,00 млн
384,00 млн
561,00 млн
Effective tax rate
25,96%
29,51%
26,12%
17,32%
Other operating expenses
-
-
-
-
Net income
1,31 млд
2,20 млд
1,09 млд
2,68 млд
Net profit margin
10,68%
18,01%
8,69%
23,30%
Earnings per share
1,46
1,63
1,26
1,58
Interest and investment income
139,00 млн
161,00 млн
148,00 млн
-
Interest expense
-485,00 млн
-482,00 млн
-432,00 млн
-
Net interest expenses
-346,00 млн
-321,00 млн
-284,00 млн
-
Depreciation and amortization charges
-
-
-
-
EBITDA
5,12 млд
4,91 млд
4,54 млд
3,96 млд
Gain or loss from assets sale
-7,00 млн
-9,00 млн
-
-34,00 млн
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer